NEWS September 28, 2017
Story in BioWorld by Michael Fitzhugh. Preliminary data on three additional patients enrolled in a small open-label study of Immune Pharmaceuticals Inc.’s bertilimumab, an experimental treatment for the rare blistering disease bullous pemphigoid (BP), continued to suggest it may offer an effective alternative to systemic corticosteroids, a standard but imperfect therapy for the condition. Immune, which is seeking an […]
NEWS February 23, 2017
Watch our latest interview with Immune CEO Daniel Teper and Jane King
NEWS November 18, 2016
Immune Pharmaceuticals Inc. CEO Daniel Teper speaks with Jane King, of Small Cap Nation, and John McCamant, of Bioinvest.com, about Immune’s new financing deal, as well as the future direction of the company. Check it out here.
NEWS November 1, 2016
SCN’s Jane King sits down with Dr. Daniel Teper, CEO & Founder of Immune Pharmaceuticals Inc. (NASDAQ: IMNP), and Chief Medical Officer Dr. Monica Luchi, to discuss the biopharmaceutical company and its future outlook.
NEWS May 5, 2016
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also […]
NEWS May 2, 2016
Let Volatility Power Your Micro-Cap Biotechs RNN, IMNP, TG, ADRO Source: George Mack of The Life Sciences Report (4/27/16) ROTH Capital Partners’ Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can’t help but drive a stock, no matter how far into the depths it may have sunk. In this interview with The […]
NEWS April 21, 2016
A team of researchers from Gothenburg University in Sweden presented data from a Phase 4 study on Ceplene® earlier this week at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA. These data could have a profound impact on future use of the drug in elderly patients with Acute Myeloid Leukemia (AML). […]
NEWS April 7, 2016
Ari Zoldan | Thursday, 07 April 2016 17:08 (EST) Immune Pharmaceuticals is competing with industry giants Regeneron and Sanofi and mid-cap company Anacor Pharmaceuticals, in an attempt to cure eczema. The micro-stock and its competitors are in the process of developing drugs for atopic dermatitis (AD), the most common form of chronic eczema. According to Dr. Neil Korman, […]